Skip to content
AnimalEndogenous Y2 receptor agonist for satiety

Peptide YY (PYY 3-36)

Natural appetite-suppressing gut peptide.

Overview

Binds to Y2 receptors on NPY/AgRP neurons in the hypothalamus, inhibiting orexigenic signaling and reducing food intake.

Proposed mechanism

PYY 3-36 is a naturally occurring gut hormone that binds to Y2 receptors in the hypothalamus (arcuate nucleus), reducing NPY release and appetite.

What the evidence supports

Most data comes from preclinical animal studies. Human clinical trial evidence is limited or absent.

Graded Animal

Evidence drawn from in vivo animal models or in vitro systems. Mechanistically informative; translation to humans is unproven.

Key citations

Representative primary sources, including results that did not favour the compound.

  1. [1]

    PYY 3-36 in obesity

    · DOI:10.1056/NEJMoa023200 · 2003

  2. [2]

    PYY pharmacology

    · DOI:10.1038/nrd.2016.100 · 2016

  3. [3]

    PYY 3-36 in obesity (2003)

    · · 0

  4. [4]

    PYY pharmacology (2016)

    · · 0

Citation records in this build are illustrative placeholders for the design.

Reference information for research purposes. Not medical advice, and not a recommendation to use any compound. Many entries describe substances that are not approved for human use.

Related profiles

Adipotide (FTTP)

Animal

Targeted fat-depot destruction via vascular apoptosis

Adipotide (also called FTTP) is an experimental peptidomimetic compound designed to selectively destroy the blood supply to white adipose tissue by targeting prohibitin, a protein highly expressed on the vasculature feeding fat cells. Originally developed at MD Anderson Cancer Center, it demonstrated dramatic fat loss in obese rhesus monkeys without dietary restriction. It remains a research compound with no approved human clinical use.

0 RCT · 0 human · 0 preclinical

fat-loss

AICAR

Human-limited

AMPK activator mimicking endurance exercise effects

AICAR (Acadesine) is a nucleoside analog and potent AMPK activator that mimics the cellular energy-depletion state, triggering a cascade of metabolic adaptations including enhanced fatty acid oxidation and mitochondrial biogenesis. It has been extensively studied for its ability to improve endurance performance, insulin sensitivity, and metabolic flexibility without physical exercise. Originally developed as a cardioprotective agent, it has attracted significant interest in the performance and longevity research communities.

0 RCT · 0 human · 0 preclinical

metabolic

AOD-9604

Anecdotal

HGH fragment for lipolysis stimulation

HGH fragment for localized fat metabolism.

0 RCT · 0 human · 0 preclinical

fat-loss